Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.

Publication ,  Journal Article
Liu, W; Cai, Q; Yu, T; Strati, P; Hagemeister, FB; Zhai, Q; Zhang, M; Li, L; Fang, X; Li, J; Sun, R; Zhang, S; Yang, H; Wang, Z; Qian, W ...
Published in: Am J Cancer Res
2022

Castleman disease (CD) has been reported as a group of poorly understood lymphoproliferative disorders, including unicentric CD (UCD) and idiopathic multicentric CD (iMCD) which are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative. The clinical and independent prognostic factors of CD remain poorly elucidated. We retrospectively collected the clinical information of 428 patients with HIV and HHV-8 negative CD from 12 large medical centers with 15-year follow-up. We analyzed the clinicopathologic features of 428 patients (248 with UCD and 180 with iMCD) with a median age of 41 years. The histology subtypes were hyaline-vascular (HV) histopathology for 215 patients (56.58%) and plasmacytic (PC) histopathology for 165 patients (43.42%). Most patients with UCD underwent surgical excision, whereas the treatment strategies of patients with iMCD were heterogeneous. The outcome for patients with UCD was better than that for patients with iMCD, 5-year overall survival (OS) rates were 95% and 74%, respectively. In further analysis, a multivariate analysis using a Cox regression model revealed that PC subtype, hepatomegaly and/or splenomegaly, hemoglobin ≤ 80 g/L, and albumin ≤ 30 g/L were independent prognostic factors of CD for OS. The model of iMCD revealed that age > 60 years, hepatomegaly and/or splenomegaly, and hemoglobin ≤ 80 g/L were independent risk factors. In UCD, single-factor analysis identified two significant risk factors: hemoglobin ≤ 100 g/L and albumin ≤ 30 g/L. Our study emphasizes the distinction of clinical characteristics between UCD and iMCD. The importance of poor risk factors of different clinical classifications may direct more precise and appropriate treatment strategies.

Duke Scholars

Published In

Am J Cancer Res

ISSN

2156-6976

Publication Date

2022

Volume

12

Issue

9

Start / End Page

4227 / 4240

Location

United States

Related Subject Headings

  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Liu, W., Cai, Q., Yu, T., Strati, P., Hagemeister, F. B., Zhai, Q., … Yu, L. (2022). Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up. Am J Cancer Res, 12(9), 4227–4240.
Liu, Wanying, Qingqing Cai, Tiantian Yu, Paolo Strati, Frederick B. Hagemeister, Qiongli Zhai, Mingzhi Zhang, et al. “Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.Am J Cancer Res 12, no. 9 (2022): 4227–40.
Liu W, Cai Q, Yu T, Strati P, Hagemeister FB, Zhai Q, et al. Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up. Am J Cancer Res. 2022;12(9):4227–40.
Liu W, Cai Q, Yu T, Strati P, Hagemeister FB, Zhai Q, Zhang M, Li L, Fang X, Li J, Sun R, Zhang S, Yang H, Wang Z, Qian W, Iwaki N, Sato Y, Oksenhendler E, Xu-Monette ZY, Young KH, Yu L. Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up. Am J Cancer Res. 2022;12(9):4227–4240.

Published In

Am J Cancer Res

ISSN

2156-6976

Publication Date

2022

Volume

12

Issue

9

Start / End Page

4227 / 4240

Location

United States

Related Subject Headings

  • 1112 Oncology and Carcinogenesis